All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-10-16T11:07:08.000Z

FDA advisory committee recommends approval of CT-P10 for the treatment of non-Hodgkin lymphoma

Oct 16, 2018
Share:

Bookmark this article

The U.S Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) have unanimously voted 16 to 0 in favor of allowing CT-P10 (Truxima®), a monoclonal antibody (mAb) biosimilar to rituximab (Rituxan®), to be approved for the treatment of patients with non-Hodgkin lymphoma (NHL). The proposed indication for CT-P10 are for patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent, previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy and non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy.

The ODAC discussions were based on the data in a biologics license application (BLA) for CT-P10, which is shown that CT-P10 demonstrated bio-similarity between CT-P10 and rituximab in terms of efficacy, safety, pharmacology, analytical similarity, and immunogenicity.

The BLA for CT-P10 was based on results obtained from two randomized, double-blinded trials (NCT02162771 and NCT02260804). Data from both studies demonstrated that there were no clinically meaningful differences between CT-P10 and rituximab (Rituxan®).

  1. Targeted Oncology: ODAC Recommends FDA Approval of Rituximab Biosimilar. 2018 Oct 10. https://www.targetedonc.com/news/odac-recommends-fda-approval-of-rituximab-biosimilar [Accessed 2018 Oct 15].
  2. BusinessWire: Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar. 2018 Oct 10. https://www.businesswire.com/news/home/20181010005787/en/Celltrion-Teva-Announce-FDA-Oncologic-Drugs-Advisory [Accessed 2018 Oct 15].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox